Last SFr.0.34 CHF
Change Today -0.02 / -5.56%
Volume 840.1K
CYTN On Other Exchanges
SIX Swiss Ex
As of 11:43 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

cytos biotechnology ag-reg (CYTN) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/3/14 - SFr.3.70
52 Week Low
04/14/14 - SFr.0.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cytos biotechnology ag-reg (CYTN) Related Businessweek News

No Related Businessweek News Found

cytos biotechnology ag-reg (CYTN) Details

Cytos Biotechnology AG, a biopharmaceutical company, focuses on the discovery, development, and commercialization of biopharmaceutical products for use in the treatment and prevention of chronic diseases in Switzerland. The company’s lead product candidate is CYT003, which has completed Phase 2b clinical trials for the treatment of allergic asthma. It is developing CYT003 using Qb VLP platform, a vaccine platform based on bacteriophage Q beta-derived virus-like particles (Qb VLPs), which act as immune-stimulatory carriers for disease-associated antigens. The company has collaboration agreements with Novartis for the development of CAD106, an active immunotherapy for the treatment of patients with Alzheimer’s disease; Pfizer for developing a novel anti-IgE vaccine for Qb VLP platform; and Singapore’s Agency for Science, Technology and Research for the research, development, and commercialization of an influenza vaccine. Cytos Biotechnology AG is based in Schlieren, Switzerland.

28.2 Employees
Last Reported Date: 09/30/14

cytos biotechnology ag-reg (CYTN) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: SFr.701.7K
Compensation as of Fiscal Year 2013.

cytos biotechnology ag-reg (CYTN) Key Developments

Cytos Biotechnology AG Exclusively Licenses VLP Platform for the Treatment of Hepatitis B Infections to OnCore Biopharma

Cytos Biotechnology Ltd. announced that it executed an exclusive license agreement granting OnCore Biopharma Inc. access to Cytos' clinically validated virus like particle (VLP) platform for the use in the treatment and prevention of hepatitis B viral infections. Cytos also granted an option for the treatment of additional viral diseases other than influenza. The agreement will become effective with the achievement of certain closing conditions, including a successful debt restructuring of Cytos. For the first product in each of six possible product categories in the field of Hepatitis B that may be developed under the agreement, Cytos may receive up to USD 67 million in development milestones, or a maximum of USD 402 million if one product in each product category is developed. In addition, Cytos is eligible to receive commercial milestone payments of up to USD 120 million upon achievement of certain sales levels, and up to double-digit royalties on net sales from any successfully developed product.

Cytos Biotechnology AG Announces the Resignation of Matthias Alder as Executive Vice President Corporate Development and Legal Affairs

Cytos Biotechnology AG announced that Mr. Matthias Alder, Executive Vice President Corporate Development and Legal Affairs, resigns from his function effective as of October 27, 2014. The departure of Mr. Alder follows in the course of the winding down of key operational activities of the Company. Mr. Alder has agreed to continue his service to the Company as a consultant until February 28, 2015 to complete ongoing projects and facilitate the transition of his responsibilities.

Cytos Biotechnology Ltd. Reports Consolidated Earnings Results for the Six Months Period Ended June 30, 2014

Cytos Biotechnology Ltd. reported consolidated earnings results for the six months period ended June 30, 2014. For the six months, the company reported revenue of CHF 0.5 million compared to CHF 0.5 million a year ago. Operating loss was CHF 16.0 million compared to CHF 10.0 million a year ago. Net loss was CHF 23.4 million compared to CHF 13.6 million a year ago. Net loss per share was CHF 0.77 compared to CHF 0.61 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTN:SW SFr.0.34 CHF -0.02

CYTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTN.
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTOS BIOTECHNOLOGY AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at